Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Rhea-AI Summary

Phathom Pharmaceuticals (NASDAQ: PHAT) has announced it will host a live webcast on Thursday, March 6, 2025, at 8:30 am ET to present its fourth quarter and full year 2024 financial results along with a business update.

The company specializes in developing and commercializing treatments for gastrointestinal diseases. Their key product is vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) marketed in the US as VOQUEZNA®. The treatment is approved for heartburn associated with Non-Erosive GERD in adults, healing and maintenance of Erosive GERD, and comes in TRIPLE PAK® and DUAL PAK® combinations for H. pylori infection treatment.

• Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET
  
  

FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 6, 2025, to report its fourth quarter and full year 2024 financial results and provide a business update.

A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

FAQ

When will Phathom Pharmaceuticals (PHAT) report Q4 and FY 2024 earnings?

Phathom Pharmaceuticals will report its Q4 and full year 2024 financial results on Thursday, March 6, 2025, at 8:30 am ET via a live webcast.

What treatments does Phathom Pharmaceuticals (PHAT) currently market in the US?

Phathom markets VOQUEZNA (vonoprazan) tablets for GERD treatment, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK for H. pylori infection in adults.

How can investors access Phathom Pharmaceuticals' (PHAT) Q4 2024 earnings webcast?

Investors can access the webcast through the Events & Presentations section of Phathom's website at investors.phathompharma.com. A recording will be available for 90 days after the event.

What are the approved indications for VOQUEZNA by Phathom Pharmaceuticals (PHAT)?

VOQUEZNA is approved for heartburn associated with Non-Erosive GERD in adults, healing and maintenance of healing of Erosive GERD in adults, and H. pylori infection treatment.